Top news of the week: 07.04.2020.
Biotechnology, Medicine, Dot-com bubble, The Canon of Medicine, Initial public offering, Collective investment scheme
Startups
Big biotech venture funds raise billions despite coronavirus fears
These are difficult times. But two of the top biotech venture firms just raised a total of $2.6 billion to fund new startups.
RT @LifeSciVC: "Small companies are relying more on contract researchers as social-distancing guidelines limit the work they can do in-house" - nice piece by @WSJ's Brian Gormley, with contributions from @accent_tx CEO Shakti Narayan and @IFMThera CEO Martin Seidel. https://t.co/EpP0J5E3fo
OpenBiotech Startups Hoping to ‘Thrive’ Amid Coronavirus Chaos
Biotechnology entrepreneurs are struggling with questions about how to keep clinical trials and other operations running despite the new coronavirus threat.
RT @Xconomy: .@FlagshipPioneer Adds $1.1B for New Meds, More AI, & “Health Security”
- by @sarahdc; insight from CEO @NoubarAfeyan
https://t.co/L32LEY9bas
OpenFlagship Adds $1.1B for New Meds, More AI, & “Health Security”
Flagship Pioneering founder and CEO Noubar Afeyan didn’t know a global pandemic was in the cards for 2020 when he and his team laid out three new thematic
Of course.
Martin Shkreli is trying to use the coronavirus pandemic to get out of prison, @adamfeuerstein and @damiangarde tell us.
https://t.co/h6hq7fugmq
OpenMartin Shkreli is trying to use the coronavirus pandemic to get out of prison
Martin Shkreli has a pitch to authorities: Let me out of prison for a few months and I’ll help stop the novel coronavirus.
RT @FierceBiotech: While the world and amount of money available to Arch have changed since it raised its ninth set of funds, the VC shop will continue to follow the same broad playbook. https://t.co/GQ26Kqm7IV
OpenArch raises $1.5B to back early stage biotechs through accelerating 'healthcare revolution'
Arch Venture Partners has raised $1.5 billion to place another round of bets on early-stage biotechs. The VC shop, which lists Alnylam and Juno among its previous investments, raised the ...
Vantage called 2019 a retreat for biotech VC, “but not by much,” in its 2019 Review. https://t.co/iZerPTw9Ub
OpenTop biotech money raisers of 2019
At first glance, venture investment for biotech slumped in 2019. By the raw numbers, 2019 lost on every metric compared to 2018. Total investment dollars dropped by $4 billion, from $17.9 ...
In April, we spoke with Yohan Tessier of @misprobiotech about the great work they're doing to advance #LifeSciences. Learn how Mispro is cultivating innovation in science through a coworking #vivarium & how it’s enabling #DrugDiscovery: https://t.co/nuK70zo2ck #MemberSpotlight https://t.co/bgxA4s6QGn
OpenMember Spotlight: Q&A with Mispro Biotech Services
Yohan has been on the forefront of Mispro’s growth from a single facility to becoming North America’s leading contract vivarium company with facilities in all major U.S. biotech …
Biotech startup receives FDA approval for potential Covid-19 treatment, to begin human trials immediately @wheresKR https://t.co/Cak3zcaFJj
OpenBiotech Startup Wins FDA Approval for Potential Covid-19 Treatment
Stem cell therapy startup Celularity says it will begin human trials immediately.